Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-5933 in advanced KRAS p.G12C mutant solid tumors
NCT06006793Phase 1Unknown
- Sponsor
- Shouyao Holdings
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SY-5933 in solid tumor, sponsored by Shouyao Holdings. Primary endpoints: Incidence of Dose-limiting toxicities at 31 days and Number of participants with adverse events at 18 months. Status: unknown.
02
Drugs
SY-5933
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06006793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006793.